The Exciting World of Macrocycle Structures
In this post, we discuss the unique structure of macrocyclic peptide drugs (often 4 to 24 amino acids), which falls between small-molecule drugs and biologics (such as monoclonal antibodies).
Outsourcing to CROs is on the rise. What benefits does it provide?
The expansion of the drug discovery CRO market highlights the need to minimize costs and timelines in pharmaceutical drug development. Discover how SARomics Biostructures can help with this!
How was our 2024?
It was a year marked by the most significant changes in recent memory: a new home for the company, four new team members, new collaborations, new publications, a revamped homepage, and a greatly expanded list of off-the-shelf structures.
DNA-Encoded Library Screening For Drug Discovery
SARomics Biostructures AB and Vipergen ApS partner to offer hit and lead identification services based on Vipergen’s unique DNA-encoded library (DEL) screening technology.
The Power Of NMR in Biosimilars Comparability Assessment
In the this article we discuss evidence that shows that NMR spectroscopy is far superior to other established methods for biosimilar’s comparability assessment.
WAC™ Fragment screening technology: Principles & Advantages
In this article, we discuss weak affinity chromatography (WAC™), the proprietary fragment screening technique jointly owned by SARomics Biostructures and Red Glead Discovery.
2023 – More Structural Biology & Drug Discovery
In this article, we will discuss some significant publications and company activities in 2023. The publications showcase our expertise in the three main areas of our services: X-ray crystallography, NMR spectroscopy, and integrated drug discovery.
Room-Temperature Crystallography In Drug Design
In this post we want to bring to the attention of our readers the revival of room-temperature (RT) protein crystallography using synchrotron radiation and its potential applications in structure-based drug design to study of functionally-important conformations.
Biosimilars: Structure Comparability Analysis
In the second part of our article series on antibody therapeutics, we discuss biosimilars and their structure comparability analysis.
Aqilion’s TAK1 inhibitor secures alliance worth € 950 million
Using an integrated drug discovery approach, first-in-class TAK1 kinase inhibitors were designed in a hit-to-lead program run in close cooperation between three partners, SARomics Biostructures, Red Glead Discovery, and Aqilion.